Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E₂ levels

References

• Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14–22
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801
   PubMed Web of Science ®Google Scholar
• Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, Mizushima T. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003; 278: 12752–8
   PubMedGoogle Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790–804
   PubMed Web of Science ®Google Scholar
• Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62: 167–215
   PubMed Web of Science ®Google Scholar
• Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase-2 implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 443–53
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255–8
   PubMed Web of Science ®Google Scholar
• Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998; 95: 14540–5
   PubMed Web of Science ®Google Scholar
• Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304–12
   PubMed Web of Science ®Google Scholar
• Verstraete M. Primary and secondary prevention of arterial thromboembolism. Br Med Bull 1994; 50: 946–65
   PubMedGoogle Scholar
• Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827–30
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–8
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and non-aspirin non-steroidal anti-inflammatory drugs. Am J Epidemiol 2004; 159: 23–31
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81
   PubMed Web of Science ®Google Scholar
• Venerito M, Treiber G, Wex T, Kuester D, Roessner A, Di Mario F, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 1225–33
   PubMed Web of Science ®Google Scholar
• Garcia RL, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and non-aspirin non-steroidal anti-inflammatory drugs. Am J Epidemiol 2004; 159: 23–31
   PubMed Web of Science ®Google Scholar
• Feldman M, Cryer B, Mallat D, Go MF. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long-term/low-dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol 2001; 96: 1751–7
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Naesdal J, Wilson I, Långström G, Swannell AJ, Peacock RA, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51: 336–43
   PubMedGoogle Scholar
• Hawkey C, Tulassay Z, Szczepanski L, van Rensburg CG, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016–21
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65–9.
   PubMed Web of Science ®Google Scholar
• Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 1997; 29: 671–8
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–81
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Enrique Domínguez-Muñoz J, Heckenmuller H, Neubrand M, Fischer HP, Sauerbruch T. Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996; 8: 53–6
   PubMedGoogle Scholar
• Leodolter A, Dominguez-Munoz JE, von Arnim U, Kahl S, Peitz U, Malfertheiner P. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 2100–4
   PubMedGoogle Scholar
• Wex T, Treiber G, Lendeckel U, Malfertheiner P. A two-step method for the extraction of high-quality RNA from endoscopic biopsies. Clin Chem Lab Med 2003; 41: 1033–7
   PubMedGoogle Scholar
• Rosenstock S, Jorgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population-based prospective cohort study comprising 2416 Danish adults. Gut 2003; 52: 186–93
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99
   PubMed Web of Science ®Google Scholar
• Cohen MM, MacDonald WC. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leuk Med 1982; 9: 241–55
   PubMedGoogle Scholar
• Kauffman G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 1989; 96: 606–14
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B. Drug insight: aspirin resistance – fact or fashion?. Nat Clin Pract Cardiovasc Med 2007; 4: 42–50
   PubMedGoogle Scholar
• Cryer B, Feldman M. Effects of very low-dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17–25
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Dominguez-Munoz JE. Rationale for eradication of Helicobacter pylori infection in duodenal ulcer disease. Clin Ther 1993;15, Suppl B:37–48.
   PubMedGoogle Scholar
• Mertz-Nielsen A, Hillingso J, Frokiaer H, Bukhave K, Rask-Madsen J. Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori-positive healthy subjects. Scand J Gastroenterol 1996; 31: 38–43
   PubMed Web of Science ®Google Scholar
• Cryer B, Faust TW, Goldschmiedt M, Redfern JS, Lee E, Feldman M. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992; 87: 1747–54
   PubMed Web of Science ®Google Scholar
• Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med 1992; 116: 636–40
   PubMed Web of Science ®Google Scholar
• Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723–7
   PubMed Web of Science ®Google Scholar
• Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371–86
   PubMed Web of Science ®Google Scholar
• Damm J, Rau T, Maihofner C, Pahl A, Brune K. Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body. Exp Eye Res 2001; 72: 611–21
   PubMedGoogle Scholar
• Ziegler EA, Brieger J, Heinrich UR, Mann WJ. Immunohistochemical localization of cyclooxygenase isoforms in the organ of corti and the spiral ganglion cells of guinea pig cochlea. ORL J Otorhinolaryngol Relat Spec 2004; 66: 297–301
   PubMed Web of Science ®Google Scholar
• Walenga RW, Kester M, Coroneos E, Butcher S, Dwivedi R, Statt C. Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins 1996; 52: 341–59
   PubMedGoogle Scholar